Takeda says IgGNITE Phase 2/3 trial shows TAK — 881 matches HyQvia pharmacokinetics in PID patients 16+
Takeda presented detailed Phase 2/3 IgGNITE results for investigational subcutaneous TAK-881 in primary immunodeficiency disease at ESID 2026. The study met its primary endpoint, supporting comparability to Takeda’s marketed HYQVIA in patients aged 16 and older. Descriptive findings indicated similar infection protecti